Quantcast

Latest Acute myeloid leukemia Stories

2014-06-04 08:30:46

SAN DIEGO, June 4, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the appointment of Jeffrey S. Hatfield to its Board of Directors and the resignation of board member Steven Elms. "Jeff has a great deal of business and pharmaceutical expertise and we are excited to welcome him to Ambit's board of directors," said...

2014-06-03 20:21:34

SAN DIEGO, June 3, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced two poster presentations at the Annual Meeting of the American Society of Clinical Oncology, held May 30 through June 3, 2014, at McCormick Place in Chicago. Final Results of a Randomized Phase 2 Study Showing the Clinical Benefit of quizartinib (AC220) in...

2014-05-29 15:51:33

University of Chicago Medical Center Pinpointing cause of relapse could lead to better therapies A multi-institutional team of researchers has pinpointed exactly what goes wrong when chronic lymphocytic leukemia (CLL) patients develop resistance to ibrutinib, a highly effective, precisely targeted anti-cancer drug. In a correspondence published online May 28 in the New England Journal of Medicine, they show how the mutation triggers resistance. Their finding could guide development of...

2014-05-22 16:26:35

The Leukemia & Lymphoma Society and Oregon Health & Sciences University forged Beat AML collaboration to find effective therapies for acute myeloid leukemia patients WHITE PLAINS, N.Y., May 22, 2014 /PRNewswire-USNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced a $4 million commitment by the Harry T. Mangurian, Jr. Foundation to support a groundbreaking collaboration between LLS and with Brian Druker, M.D., of Oregon Health and Science University to "Beat...

2014-05-15 23:02:22

Dr. Beverly J. Lange, an exemplary physician and researcher at The Children's Hospital of Philadelphia for over 40 years, will receive the Distinguished Career Award from the American Society of Pediatric Hematology/Oncology. Philadelphia, Pa (PRWEB) May 15, 2014 Beverly J. Lange, M.D., an exemplary physician and researcher at The Children’s Hospital of Philadelphia(CHOP) for over 40 years, will receive the 2014 Distinguished Career Award from the American Society of Pediatric...

2014-05-07 08:32:14

First-in-class DOT1L Inhibitor in Clinical Development as Potential Personalized Therapeutic for Patients with Genetically Defined Acute Leukemias CAMBRIDGE, Mass., May 7, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the initiation of a Phase 1b open-label clinical study of EPZ-5676 in pediatric patients with acute leukemias...

2014-05-06 16:33:03

Quizartinib QUANTUM-R Phase 3 Trial Begins SAN DIEGO, May 6, 2014 /PRNewswire/ -- Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced operating results for the first quarter 2014. The company will host a conference call today to discuss financial results for the first quarter, and to provide an update on plans and activities for 2014. "We...

2014-04-25 09:23:29

CPX-351 treatment leads to higher chances of remission compared to standard options in AML Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine and daunorubicin, are showing better responses than patients treated with the standard drug formulation. "Acute myeloid leukemia is an aggressive blood cancer with very low...

2014-04-22 08:32:37

SAN DIEGO, April 22, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced it will report first quarter operational results after closing of the NASDAQ Global Market on Tuesday, May 6, 2014. A conference call hosted by Michael Martino, president and CEO, and other members of senior management will take place on the same...

2014-04-17 08:28:00

RIDGEFIELD, Conn., April 17, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation to volasertib for acute myeloid leukemia (AML). Volasertib is currently being evaluated in a Phase III clinical trial for the treatment of patients aged 65 or older, with previously untreated AML, who are ineligible for intensive remission induction therapy....


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related